Nov 29, 2017

The Partners in Bleeding Disorders Education Program recently launched “Psychosocial Considerations in Bleeding Disorder Care: Birth to Preadolescence.” This online learning activity is focused on the developmental and psychosocial issues unique to children with bleeding disorders, specifically those from infancy through preadolescence. The activity also encompasses the psychosocial considerations that may be seen in families of affected children.     

The module is targeted to social workers, nurses, and other healthcare professionals in the federally recognized US hemophilia treatment center network (USHTCN) interested in learning more about the psychosocial considerations of care for children and preadolescents with bleeding disorders

This module is available until 5:00pm Eastern Time, June 30, 2018.

This activity is provided for 1.00 contact hours under American Nurses Credentialing Center (ANCC) criteria. The University of Nebraska Medical Center College of Nursing Continuing Nursing Education is accredited as a provider of continuing nursing education by ANCC’s Commission on Accreditation.

This program is also Approved by the National Association of Social Workers (Approval # 886604222-2149) for 1.0 continuing education contact hours.

Established in 1996, the Partners Program promotes excellence in care through education created by and for the federally recognized HTC Network and providers from a variety of disciplines that serve patients with bleeding and other coagulation disorders. The program is a collaborative initiative of the Indiana Hemophilia & Thrombosis Center, NHF, and the Hemophilia Foundation of Michigan. Funding to support the Partners in Bleeding Disorders Education Program is provided through an unrestricted educational grant from Shire.

Learn more about “Psychosocial Considerations in Bleeding Disorder Care: Birth to Preadolescence,” and other online educational activities by going to the PartnersPRN web site,


Stay connected with us! Subscribe to receive the latest news on treatments, clinical trials, advocacy issues, and NHF events.

Related News